Journal
VACCINE
Volume 30, Issue -, Pages F83-F87Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2012.04.106
Keywords
HPV; virus like particle; VLP; antibody; B cells; L1 protein; L2 protein; cell mediated immunity
Categories
Ask authors/readers for more resources
Prophylactic human papillomavirus (HPV) virus-like particle (VLP) vaccines are highly effective. The available evidence suggests that neutralising antibody is the mechanism of protection. However, despite the robust humoral response elicited by VLP vaccines, there is no immune correlate, no minimum level of antibody, or any other immune parameter, that predicts protection against infection or disease. The durability of the antibody response and the importance of antibody isotype, affinity and avidity for vaccine effectiveness are discussed. Once infection and disease are established, then cellular immune responses are essential to kill infected cells. These are complex processes and understanding the local mucosal immune response is a prerequisite for the rational design of therapeutic HPV vaccines. This article forms part of a special supplement entitled Comprehensive Control of HPV Infections and Related Diseases Vaccine Volume 30, Supplement 5, 2012. (C) 2012 Published by Elsevier Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available